| 2025 | | Platform study of circulating tumor DNA directed adjuvant chemotherapy in colon cancer (CLAUDIA colon cancer, KCSG CO22-12)
BMC cancer, 25(1). : 1373-1373, 2025 | 강석윤 |
| 2025 | | Safety Evaluation of SH003 and Docetaxel Combination in Patients With Breast and Lung Cancer: A Multi-Center, Open-Label, Dose Escalation Phase I Clinical Trial
Integrative cancer therapies, 24. : 15347354251363892-15347354251363892, 2025 | 강석윤 |
| 2025 | | Analysis of outcomes according to start timing of adjuvant chemotherapy in patients with gastric cancer: a retrospective nationwide cohort study
The oncologist, 30(6). : oyaf132-oyaf132, 2025 | 강석윤, 권민석, 김태환, 박범희, 안미선, 이현우, 최용원, 최진혁 |
| 2025 | | Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study
The Lancet. Oncology, 26(3). : 343-354, 2025 | 강석윤 |
| 2024 | | Clinical application of whole-genome sequencing of solid tumors for precision oncology
Experimental & molecular medicine, 56(8). : 1856-1868, 2024 | 강석윤, 고영화, 곽규성, 권민석, 김석휘, 김선일, 김세혁, 김장희, 김재근, 김창우, 김철호, 김태환, 노성현, 노진, 노충균, 박지원, 박지은, 백수연, 손상용, 신승수, 안미선, 양민재, 유우식, 윤재성, 이기명, 이길호, 이다근, 이현우, 임선교, 장전엽, 정윤정, 조대성, 최용원, 최진혁, 하태양, 한상욱, 허지미, 허훈 |
| 2024 | | Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY
Journal of clinical oncology, 42(25). : 2961-2965, 2024 | 강석윤 |
| 2024 | | A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer
NPJ breast cancer, 10(1). : 76-76, 2024 | 강석윤 |
| 2024 | | Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial
Nature communications, 15(1). : 2153-2153, 2024 | 강석윤 |
| 2024 | | Treatment Patterns and Prognosis of Palliative Chemotherapy Combined With Targeting Agents in Patients With Unresectable Metastatic Colorectal Cancer: CHOICE, A Multicenter Longitudinal Observational Study
Anticancer research, 44(1). : 347-359, 2024 | 강석윤 |
| 2024 | | Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study
BMC cancer, 24(1). : 70-70, 2024 | 강석윤, 고영화, 김태환, 신승수, 안미선, 이현우, 최용원, 최진혁 |
| 2023 | | Thromboembolic events in patients who received adjuvant chemotherapy for gastric cancer: a single-center retrospective study
Gastric cancer, 26(6). : 1012-1019, 2023 | 강석윤, 권민석, 김태환, 손상용, 신승수, 안미선, 이현우, 최용원, 최진혁, 한상욱, 허훈 |
| 2022 | | The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study
The Korean journal of internal medicine, 37(2). : 434-443, 2022 | 강석윤, 김세혁, 노오규, 노태훈, 신승수, 안미선, 오영택, 이현우, 최용원, 최진혁 |
| 2022 | | Erratum: Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
The Korean journal of internal medicine, 37(6). : 1269-1269, 2022 | 강석윤, 김철호, 김태환, 신승수, 신유섭, 안미선, 오영택, 이현우, 장전엽, 최용원, 최진혁, 허재성 |
| 2022 | | Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
The Korean journal of internal medicine, 37(3). : 653-659, 2022 | 강석윤, 김철호, 김태환, 신승수, 신유섭, 안미선, 오영택, 이현우, 장전엽, 최용원, 최진혁, 허재성 |
| 2022 | | Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study
BMC cancer, 22(1). : 948-948, 2022 | 강석윤, 김태환, 안미선, 이현우, 최용원, 최진혁 |
| 2022 | | Oxaliplatin (3 months v 6 months) with 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients with Stage II/III Colon Cancer: KCSG CO09-07
Journal of clinical oncology, 40(33). : 3868-3877, 2022 | 강석윤 |
| 2022 | | Analysis of thromboembolic events in patients with non-small cell lung cancer who received adjuvant chemotherapy: single-center real-world data
Scientific reports, 12(1). : 7646-7646, 2022 | 강석윤, 김태환, 신승수, 안미선, 이현우, 최용원, 최진혁 |
| 2022 | | Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
Breast (Edinburgh, Scotland), 62. : 52-60, 2022 | 강석윤 |
| 2021 | | Significance of descriptive symptoms and signs and clinical parameters as predictors of neuropathic cancer pain
PloS one, 16(8). : e0252781-e0252781, 2021 | 강석윤 |
| 2021 | | Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data
BMC cancer, 21(1). : 325-325, 2021 | 강석윤, 김태환, 신승수, 안미선, 이현우, 조헌도, 최용원, 최진혁 |
| 2021 | | Early removal of central venous catheter may not impact the in-hospital mortality in patients with acute leukemia
Annals of hematology, 100(11). : 2825-2830, 2021 | 강석윤, 김태환, 박준성, 안미선, 이현우, 정성현, 최용원, 최윤석, 최진혁 |
| 2021 | | Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13)
Cytokine, 142. : 155487-155487, 2021 | 강석윤 |
| 2021 | | Corrigendum to ‘Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer’, [Eur J Canc 51 (2015) 482–488]
European journal of cancer (Oxford, England : 1990), 147. : 187-187, 2021 | 강석윤 |
| 2021 | | Implications of tamoxifen resistance in palbociclib efficacy for patients with hormone receptor-positive, her2-negative metastatic breast cancer: Subgroup analyses of kcsg-br15-10 (youngpearl)
Cancer research and treatment, 53(3). : 695-702, 2021 | 강석윤 |
| 2021 | | Clinicopathological and Molecular Analysis of 45 Cases of Pure Mucinous Breast Cancer
Frontiers in oncology, 10. : 558760-558760, 2021 | 강석윤, 김장희, 김태규, 노진, 안미선, 임현이, 정용식, 최진혁 |
| 2021 | | Characterizing the anticancer treatment trajectory and pattern in patients receiving chemotherapy for cancer using harmonized observational databases: Retrospective study
JMIR medical informatics, 9(4). : e25035-e25035, 2021 | 강석윤, 박래웅 |
| 2021 | | Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)
Therapeutic advances in medical oncology, 13. : 17588359211061989-17588359211061989, 2021 | 강석윤 |
| 2020 | | Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)
Cancers, 12(11). : 3265-3265, 2020 | 강석윤 |
| 2020 | | Combination versus single-agent as palliative chemotherapy for gastric cancer
BMC cancer, 20(1). : 167-167, 2020 | 강석윤, 박준성, 신승수, 안미선, 이현우, 정성현, 최용원, 최진혁 |
| 2020 | | Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial
JAMA oncology, 6(3). : e193692-e193692, 2020 | 강석윤 |
| 2019 | | The impact of systemic treatment on brain metastasis in patients with non-small-cell lung cancer: A retrospective nationwide population-based cohort study
Scientific reports, 9(1). : 18689-18689, 2019 | 강석윤, 안미선, 이현우 |
| 2019 | | Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
The Lancet. Oncology, 20(12). : 1750-1759, 2019 | 강석윤 |
| 2019 | | EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment
Annals of oncology, 30. : 23-23, 2019 | 강석윤 |
| 2019 | | Does the extent of brain metastasis affect outcome of non-small cell lung cancer patients treated with chemotherapy?
Journal of clinical oncology, 37(15_suppl). : e20616-e20616, 2019 | 강석윤, 안미선, 이현우, 최용원, 최진혁 |
| 2019 | | The impact of systemic treatment on brain metastasis in patients with non-small-cell lung cancer: A retrospective nationwide population-based cohort study
Journal of clinical oncology, 37(15_suppl). : e20572-e20572, 2019 | 강석윤 |
| 2019 | | A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10, NCT02592746)
Journal of clinical oncology, 37(15_suppl). : 1007-1007, 2019 | 강석윤 |
| 2019 | | Pertuzumab, trastuzumab, and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: Efficacy and safety analysis of a randomized phase III study in Asian patients (PEONY)
Cancer research, 79(4S). : P6-17-17-P6-17-17, 2019 | 강석윤 |
| 2019 | | Abrogation of B-Raf(V600E) induced senescence by FoxM1 expression
Biochemical and biophysical research communications, 516(3). : 866-871, 2019 | 강석윤, 김장희, 박태준, 최용원 |
| 2019 | | S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
Cancer research and treatment, 51(1). : 1-11, 2019 | 강석윤 |
| 2019 | | The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study
The Korean journal of internal medicine, 34(1). : 165-177, 2019 | 강석윤 |
| 2019 | | The role of surgical resection before palliative chemotherapy in advanced gastric cancer
Scientific reports, 9. : 4136-4136, 2019 | 강석윤, 박준성, 손상용, 신승수, 안미선, 이현우, 정성현, 최용원, 최진혁, 한상욱, 허훈 |
| 2018 | | Should combination chemotherapy be used in all advanced gastric cancer patients?
Journal of clinical oncology, 36(15S). : e16081-e16081, 2018 | 강석윤, 안미선, 이현우, 최용원, 최진혁 |
| 2018 | | Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in gastric cancer patients who underwent palliative chemotherapy
Journal of clinical oncology, 36(15S). : e16008-e16008, 2018 | 강석윤, 안미선, 이현우, 최용원, 최진혁 |
| 2018 | | 469: Therapy-induced senescence associated secretory phenotype enhances breast cancer cell invasion and stemness via CXCR1/2-CXCR1/2 ligands axis
Cancer research, 78(13S). : 469-469, 2018 | 강석윤, 박준성, 박태준, 안미선, 이현우, 정성현, 최용원, 최진혁 |
| 2018 | | EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients
American journal of clinical oncology, 41(4). : 385-390, 2018 | 강석윤, 고영화, 박준성, 신승수, 이현우, 정성현, 최용원, 최진혁, 한재호 |
| 2018 | | Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy
Annals of oncology, 29(5). : 1220-1226, 2018 | 강석윤 |
| 2018 | | Strong immunoexpression of dickkopf-1 is associated with response to bortezomib in multiple myeloma
Leukemia & lymphoma, 59(11). : 2670-2678, 2018 | 강석윤, 김장희, 박준성, 안미선, 이현우, 정성현, 최용원, 최진혁, 한재호 |
| 2018 | | The role of third-line chemotherapy in recurrent or metastatic gastric cancer: A cohort study with propensity score matching analysis
Medicine, 97(39). : e12588-e12588, 2018 | 강석윤, 박준성, 신승수, 안미선, 이현우, 정성현, 최용원, 최진혁 |
| 2018 | | Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study
Cancer communications (London, England), 38(1). : 32-32, 2018 | 강석윤, 이현우 |
| 2017 | | Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis
Medicine, 96(50). : e8985-e8985, 2017 | 강석윤, 안영실, 윤준기, 이수진, 임현이 |
